A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety and the benefit of adding
pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of
care treatment for larynx cancer. The standard of care treatment will include chemotherapy
and radiation for 7 weeks.